SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Organogenesis ORG
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CMason who wrote (1118)8/25/1998 11:47:00 PM
From: Rick Strange  Read Replies (1) of 1223
 
At the Advisory Panel Review the statistics presented by the FDA, from ORGs own trial, showed that Apligraf healed fewer patients and require longer to obtain full wound closure than control...zinc oxide and pressure bandages for those ulcers of less than one year duration. Why else is Novartis rerunning the trials in Canada other than attempting to remove this negative. I have no idea where the Washington Post got the six months figure that they quoted but I believe this is an error.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News